1. Home
  2. SXC vs LBRX Comparison

SXC vs LBRX Comparison

Compare SXC & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SunCoke Energy Inc.

SXC

SunCoke Energy Inc.

HOLD

Current Price

$8.09

Market Cap

733.1M

Sector

Industrials

ML Signal

HOLD

LBRX

LB Pharmaceuticals Inc

HOLD

Current Price

$30.71

Market Cap

850.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SXC
LBRX
Founded
1960
2015
Country
United States
United States
Employees
848
27
Industry
Steel/Iron Ore
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
733.1M
850.5M
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
SXC
LBRX
Price
$8.09
$30.71
Analyst Decision
Hold
Strong Buy
Analyst Count
1
5
Target Price
$9.00
$46.60
AVG Volume (30 Days)
1.4M
218.2K
Earning Date
04-30-2026
05-06-2026
Dividend Yield
7.17%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,600,300,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
10.30
N/A
52 Week Low
$5.52
$13.40
52 Week High
$9.74
$33.47

Technical Indicators

Market Signals
Indicator
SXC
LBRX
Relative Strength Index (RSI) 40.26 59.24
Support Level $7.70 $26.75
Resistance Level $8.47 $33.47
Average True Range (ATR) 0.36 1.70
MACD -0.21 0.28
Stochastic Oscillator 1.50 69.52

Price Performance

Historical Comparison
SXC
LBRX

About SXC SunCoke Energy Inc.

SunCoke Energy Inc operates as an independent producer of coke in the Americas. Its coke is mainly used as a principal raw material in the blast furnace steelmaking process as well as in the foundry production of casted iron. The company operates through two segments: Domestic Coke and Industrial Services. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal-producing, and other manufacturing-based customers. The majority of revenue is derived from the Domestic Coke segment.

About LBRX LB Pharmaceuticals Inc

LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.

Share on Social Networks: